Feature | September 19, 2014

New Study Compares Cost-effectiveness of TAVR With Surgical Valve Replacement in High-risk Patients

Results of U.S. CoreValve High Risk trial Reported at TCT 2014

U.S. CoreValve High Risk trial TCT 2014

September 19, 2014 — According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with incremental costs considered acceptable from a U.S. perspective. Findings from the cost-effectiveness analysis of the U.S. CoreValve High Risk Trial were reported Sept. 13 at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Previous studies have shown that among patients with severe aortic stenosis who are unsuitable for conventional aortic valve surgery, TAVR provides substantial clinical benefits at a reasonable incremental cost. However, there has previously been less consensus about the cost effectiveness of TAVR relative to SAVR for high-risk surgical candidates.

Findings from the U.S. CoreValve High Risk trial, published earlier this year in the New England Journal of Medicine, found that in patients with severe, symptomatic aortic stenosis who were deemed to be at high operative risk, TAVR using a self-expanding prosthesis was associated with lower 12-month mortality compared with SAVR (14.2 percent vs. 19.1 percent).

The cost-effectiveness analysis of the U.S. CoreValve High Risk Trial compared the costs of TAVR and SAVR for this high risk population from the perspective of the US healthcare system. To assess cost effectiveness, inpatient and outpatient medical resource utilization was collected for all patients. Hospital bills were collected for 80 percent of the index hospital admissions and health state utilities were measured using the EQ-5D questionnaire at one, six and 12 months. The primary effectiveness measure was quality adjusted life years (QALY) and the secondary effectiveness measure was life years (LY).

In the as-treated population (n=747), the mean cost for the initial valve implant procedure was $23,661 higher per patient with TAVR than with SAVR ($37,920 vs. $14,258, respectively p<0.001). TAVR reduced the initial hospital length of study by 4.4 days relative to SAVR (8.1 vs. 12.5 days p<0.001) and reduced the need for rehabilitation services at discharge (23 percent vs. 44 percent, respectively p<0.001). Despite this, initial hospital costs were higher with TAVR ($69,000 vs. $58,000, including physician fees) and projected lifetime costs were also higher by approximately $13,700 per patient.

TAVR patients reported significantly better quality of life than SAVR patients at one month, but not at six or 12 months. In lifetime projections, TAVR patients were estimated to gain 0.24 life years and 0.20 quality adjusted life years relative to SAVR patients.

Projected lifetime incremental cost-effectiveness ratios for TAVR were approximately $67,000 per QALY gained and $57,000 LY gained. Results were slightly better among patients suitable for iliofemoral access (n=623) at approximately $55,500 per QALY gained and $48,300 per LY gained. Sensitivity analysis indicated that a reduction in the cost of initial TAVR hospitalizations of approximately $2,000-4,000 per patient would lower the cost effectiveness ratios to less than $50,000 per QALY or LY.

“In this high risk population, TAVR provided meaningful clinical benefits relative to SAVR, with acceptable incremental costs in the U.S.,” said lead investigator Matthew R. Reynolds, M.D., MSc. Reynolds is director, economics and quality of life research at the Harvard Clinical Research Institute.

“With modest reductions in the cost of index TAVR admissions, the value of TAVR compared with SAVR in this patient population would become high.” 

The U.S. CoreValve High Risk trial was funded by Medtronic. Reynolds reported receiving grant and research support from Medtronic and Edwards Lifesciences. He also received honoraria from Medtronic.

For more information: www.crf.org, www.tctconference.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).

Feature | Cath Lab| September 12, 2017
September 12, 2017 – The Cardiovascular Research Foundation (CRF) a
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init